Annovis Bio
ANVS
26 hedge funds and large institutions have $8.73M invested in Annovis Bio in 2022 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 5 increasing their positions, 9 reducing their positions, and 1 closing their positions.
200% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 1
8% more funds holding
Funds holding: 24 → 26 (+2)
1.46% less ownership
Funds ownership: 10.9% → 9.44% (-1.5%)
26% less capital invested
Capital invested by funds: $11.9M → $8.73M (-$3.14M)
44% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 9
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LCM
Lynwood Capital Management
Toronto,
Ontario, Canada
|
+$137K |
| 2 |
Koshinski Asset Management
Decatur,
Illinois
|
+$109K |
| 3 |
SIAP
Sterling Investment Advisors (Pennsylvania)
Berwyn,
Pennsylvania
|
+$87.5K |
| 4 |
FIA
FNY Investment Advisers
New York
|
+$33.3K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$16.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$837K |
| 2 |
Morgan Stanley
New York
|
-$589K |
| 3 |
Two Sigma Advisers
New York
|
-$310K |
| 4 |
Renaissance Technologies
New York
|
-$71K |
| 5 |
EL
Essex LLC
Deer Park,
Illinois
|
-$13K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Citigroup
New York
| – | -$765 | -70 | -93% |
|
ANVS Hedge Fund Activity: Q2 2022 in Review
26 of the 5,937 institutional investors tracked by Wall St. Rank reported a position in Annovis Bio (ANVS) for Q2 2022, worth a combined $8.73M — down 26% from $11.9M a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new ANVS positions and 1 closed out — a net gain of 2 holders — while 5 added to existing stakes and 9 trimmed.
The largest buyer was Lynwood Capital Management, opening a new position worth an estimated $137K. The largest seller was Millennium Management, exiting entirely with an estimated $837K sold.
- 26 institutional investors held Annovis Bio (ANVS) as of Q2 2022, up from 24 in Q1 2022.
- Funds reported $8.73M of Annovis Bio stock for Q2 2022, down 26% quarter-over-quarter.
- 3 funds opened new Annovis Bio positions in Q2 2022 and 1 closed out, a net change of +2 holders.
- The largest Annovis Bio buyer in Q2 2022 was Lynwood Capital Management, an estimated $137K added.
- The largest Annovis Bio seller in Q2 2022 was Millennium Management, an estimated $837K sold.
Based on aggregated 13F filings for Q2 2022.